Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
tocris mg132
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "tocris mg132" in MCE Product Catalog:
2255
2255 Publications Verification
Synonyms: Z-Leu-Leu-Leu-al; mg132
Target:
Research Areas:
MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis .
18
18 Cited Publications
Synonyms: (S,R,S)-(-)-mg-132; Z-Leu-D-Leu-Leu-al
Target:
Research Areas:
(R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132 .
1
1 Cited Publications
Cat. No.: HY-13259D
Purity: ≥98.0%
Target:
Research Areas:
MG-132 (negative control) is the negative control form of MG-132 (HY-13259) .
Research Areas:
PROTAC RAR degrader-1 (Compound 9) is a potent and selective RAR PROTAC Degrader consisting of apoptotic protein inhibitors (IAPs) ligands. IAPs-based degraders are also known as SNIPERs. PROTAC RAR Degrader-1 reduces RARα levels in HT1080 cells in a concentration-dependent manner but is blocked by the proteasome inhibitor MG132 (HY-13259). PROTAC RAR Degrader-1 can be used in the study of nuclear receptor-related diseases. (Pink: RAR ligand 1 (HY-111843); Black: Linker (HY-140189); Blue: IAPs Ligand (HY-B0134)) .
Cat. No.: HY-13259G
CAS No.: 133407-82-6
Synonyms: Z-Leu-Leu-Leu-al (GMP)
PROTAC BCR-ABL Degrader-1 is a PROTAC degrader targeting BCR-ABL, and also selectively inhibits cancer cell proliferation. PROTAC BCR-ABL Degrader-1 induces degradation via the ubiquitin-proteasome system to reduce protein levels. PROTAC BCR-ABL Degrader-1 can be used for research on chronic myeloid leukemia .
Cat. No.: HY-169358
CAS No.: 3120166-93-7
Target:
Research Areas:
L134 is a BRD4 PROTAC degrader with a DC50 of 7.36 nM. L134 induces BRD4 protein degradation without inhibiting BRD4 gene expression, and recruits the E3 ubiquitin ligase DCAF11 to mediate this process, which can be blocked by proteasome inhibitors (MG132 (HY-13259), PS341 (HY-10227)) and E1 ubiquitin ligase inhibitors (PYR41 (HY-13296), MLN4924 (HY-70062)). L134 inhibits cancer cell migration, promotes cancer cell apoptosis and exerts antiproliferative activity. L134 can be used in studies related to triple-negative breast cancer .
Cat. No.: HY-179533
Target:
Research Areas:
SOD1-aggregation-IN-1 (compound 20) is a potent SOD aggregation inhibitor. SOD1-aggregation-IN-1 inhibits MG132 (HY-13259)-induced mutant SOD1 intracellular aggregation in PC12-SOD1 G85R YFP cells with an EC50 of 2.63 μM. SOD1-aggregation-IN-1 can be used for amyotrophic lateral sclerosis (ALS) research .
Cat. No.: HY-162450
PROTAC MDM2 Degrader-8 is a PROTAC degrader that induces the degradation of the MDM2 protein by recruiting VHL. PROTAC MDM2 Degrader-8 directly binds to MDM2 with a KD of 38.2 μM; the proteasome inhibitor MG-132 (HY-13259) reverses this degradation effect, supporting that it induces MDM2 degradation via the ubiquitin-proteasome system. PROTAC MDM2 Degrader-8 also upregulates p21, induces apoptosis and cell cycle arrest, and inhibits the migration of MDA-MB-231 cells. PROTAC MDM2 Degrader-8 can be used in studies related to MDM2-targeted protein degradation and triple-negative breast cancer .
Cat. No.: HY-N9647
CAS No.: 41993-79-7
Cat. No.: HY-153582
ML 2-23 is a PROTAC degrader that recruits RNF114 to target BCR-ABL/c-ABL for degradation. ML 2-23 promotes proteasome-dependent degradation of the target protein and inhibits phosphorylation of downstream CRKL. At concentrations used for BCR-ABL degradation, ML 2-23 only causes slight impairment to the viability of cancer cells. ML 2-23 can be used in the research of chronic myeloid leukemia .
Cat. No.: HY-D3072
Research Areas:
P6-Aggrate is a fluorescent probe for aggregated proteome detection. P6-Aggrate specifically recognizes amorphous aggregated proteomes through non-covalent reversible binding, and its fluorescence enhances after heat-induced protein aggregation. P6-Aggrate reflects the polarity and compactness heterogeneity within aggregated proteomes via emission wavelength shift: short-wavelength emission (blue shift) corresponds to large aggregates with high compactness, while long-wavelength emission (red shift) corresponds to small spots with low compactness (Ex/Em = 488/520-580 nm). P6-Aggrate enables reversible monitoring of the dynamic processes of formation and clearance of stress-induced proteome aggregation such as that induced by MG132 (HY-13259) in living cells. P6-Aggrate can be used in studies related to protein homeostasis imbalance, neurodegenerative diseases and protein aggregation .
Cat. No.: HY-183078
CAS No.: 2009272-81-3
Target:
Research Areas:
P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
